Jeudi 18 Novembre 2021 de 11h00 à 12h30
Séminaire IRCM

Olivier de Wever 

University of Gent, Experimental Cancer Research Lab, Belgium

“From spheroids to extracellular vesicles: finding unknown unknowns to create minimum information guidelines and advance biological understanding”


Some more on the speaker:

Since his PhD, he has been working on cancer-associated fibroblasts (CAFs) in colon cancer progression (De Wever et al., FASEBJ 2004, J Pathol 2003, J Cell Science 2004 over 1000 cumulative WOS citations). I He expanded his research into adipose tissue during his post-doc (Lapeire et al., Cancer Res 2014) and the secretory mechanisms of pro-metastatic signals (Hendrix et al., JNCI 2010, Cancer Res 2010). His current lab woks on tumor-environment interactions  including design of model systems (De Jaeghere et al., Biomaterials 2018), response to therapy of CAFs (Tommelein et al., Cancer Res 2018), and exploitation of CAFs as therapy (De Vlieghere et al., Biomaterials 2015) and extracellular vesicles with the Hendrix lab (De Wever and Hendrix EMBOJ 2019). 

Jeudi 04 Novembre 2021 à 14h00
Séminaire IRCM

Hervé Técher

Institut de Génétique Humaine, CNRS/Université de Montpellier

Understanding the link(s) between replication stress and inflammation in cancer biology.


mercredi 15 septembre à 15h, séminaire Mabimprove

Andrew Kruse

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

“VHH antibody fragments as tools to interrogate transmembrane receptor signaling”

"Research in Dr Kruse's lab aims to elucidate the molecular basis of transmembrane signaling through the use of biochemistry, pharmacological studies, and structural biology. He is particularly interested in signaling pathways with connections to human health and disease, including G protein-coupled receptors and other transmembrane receptors. In the long term, he aims to leverage a detailed molecular understanding of these pathways to facilitate the development of new and better therapeutics."

Plus d'informations :

Jeudi 09 Septembre 2021 de 11h30 à 13h00
séminaire MabImprove-IRCM

Lloyd Bod

Evergrande Center for Immunologic Diseases, Harvard Medical School 

“Tumor-infiltrating B cells: Friends or Foes?”


Vendredi 17 Septembre 2021 de 11h00 à 13h00
Séminaire IRCM

Maria Casanova

CNIO, Madrid

Tissue-resident macrophages: helpers of early-stage lung tumor development”

Contact : Antonio Maraver



Vendredi 22 Octobre 2021 de 14h00 à 15h00
Séminaire IRCM

Manuel Collado

Santiago de Compostela University Hospital, Espagne

“Cell senescence in development, regeneration and cancer”

Contact IRCM : Antonio MARAVER

More details


jeudi 27 mai 2021, 11h, Séminaire promotionnel

Chady Jaber

Syntego Inc

“ How to Use the Power of CRISPR in Functional Genomics and Biomarkers Discovery”

This seminar dedicated to researchers at the IRCM will cover the following topics:
    • CRISPR Experimental Design and Optimization (Knock-outs and Knock-ins) 
    • Synthego robust loss of function screens for confident target discovery
    • Using CRISPR to uncover protein functions and pathway analysis

Join us for an interactive session about the latest CRISPR advances and applications. Discover the impact of CRISPR in cancer and genetic disease research.


Inscription obligatoire :

mercredi 5 mai à 11h00, séminaire MAbImprove

Sally Ward

professeur d'immunologie moléculaire et directrice de l'immunologie translationnelle au Centre d'immunologie du cancer de la faculté de médecine de l'Université de Southampton

"Targeting subcellular trafficking pathways to  design antibody-based therapeutics for cancer and autoimmunity"

Professors Sally Ward and Raimund Ober have recently relocated their research group from the USA to Southampton. Their interdisciplinary research program is dedicated to the use of protein engineering to develop novel antibody-based therapeutics.

The identification in the Ward/Ober laboratory of the Fc receptor, FcRn, as a regulator of IgG levels and transport has resulted in significant interest in targeting FcRn in biopharma. Extensive analyses of FcRn behaviour, including subcellular trafficking studies, have led to collaborations with biopharma to develop several therapeutics that are based on modulating the interactions of IgG with FcRn. For example, one such therapeutic (Efgartigimod) that inhibits FcRn activity has been developed in collaboration with Argenx, and has recently been successfully used in phase 3 trials to treat antibody-mediated autoimmune diseases.

"The presentation will cover how a combination of antibody engineering, fluorescence microscopy and mouse disease models have been used to inform the design of therapeutics to modulate the dynamic behavior of antibodies for the treatment of autoimmunity. In particular, the targeting of the MHC Class I-related receptor, FcRn, that recycles and transports IgG to maintain IgG homeostasis will be discussed. The generation of engineered antibody-drug conjugates that are designed to deliver their cytotoxic payload more efficiently to tumor cells will also be presented"

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés